Chronix Biomedical Study Demonstrates Its Blood Test Can Predict Response To Cancer Immunotherapy

Chronix Biomedical, Inc., a developer of novel cancer blood-based molecular diagnostics, announces the publication of positive results of a study using its circulating cell-free tumour DNA-based test as a means to predict therapeutic response to immunotherapy in multiple solid tumour types. Read more >>